HomeCompareCSBTF vs O

CSBTF vs O: Dividend Comparison 2026

CSBTF yields 7.18% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 O wins by $2.1K in total portfolio value· pulled ahead in Year 10
10 years
CSBTF
CSBTF
● Live price
7.18%
Share price
$27.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.2K
Annual income
$1,132.80
Full CSBTF calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — CSBTF vs O

📍 O pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSBTFO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSBTF + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSBTF pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSBTF
Annual income on $10K today (after 15% tax)
$610.41/yr
After 10yr DRIP, annual income (after tax)
$962.88/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, O beats the other by $3,374.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSBTF + O for your $10,000?

CSBTF: 50%O: 50%
100% O50/50100% CSBTF
Portfolio after 10yr
$33.2K
Annual income
$3,117.77/yr
Blended yield
9.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

CSBTF
No analyst data
Altman Z
15.0
Piotroski
4/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSBTF buys
0
O buys
0
No recent congressional trades found for CSBTF or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSBTFO
Forward yield7.18%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$32.2K$34.2K
Annual income after 10y$1,132.80$5,102.74
Total dividends collected$9.3K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: CSBTF vs O ($10,000, DRIP)

YearCSBTF PortfolioCSBTF Income/yrO PortfolioO Income/yrGap
1$11,418$718.13$10,818$608.16+$600.00CSBTF
2$12,984$766.33$11,787$741.68+$1.2KCSBTF
3$14,707$814.40$12,946$911.00+$1.8KCSBTF
4$16,599$862.14$14,345$1,127.94+$2.3KCSBTF
5$18,670$909.37$16,056$1,409.05+$2.6KCSBTF
6$20,933$955.93$18,171$1,777.83+$2.8KCSBTF
7$23,400$1,001.68$20,820$2,268.21+$2.6KCSBTF
8$26,084$1,046.47$24,188$2,929.90+$1.9KCSBTF
9$29,000$1,090.21$28,533$3,837.11+$467.00CSBTF
10← crossover$32,163$1,132.80$34,235$5,102.74$2.1KO

CSBTF vs O: Complete Analysis 2026

CSBTFStock

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

Full CSBTF Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this CSBTF vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSBTF vs SCHDCSBTF vs JEPICSBTF vs KOCSBTF vs MAINCSBTF vs STAGCSBTF vs ADCCSBTF vs NNNCSBTF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.